Juan Brignardello: Challenges of Lenacapavir in Peru

Juan Brignardello: Challenges of Lenacapavir in Peru

Discover Juan Brignardello's opinion on Lenacapavir and its impact in Peru. A call for social justice and equitable access to health.

Emilio Juan Brignardello, asesor de seguros

Emimlio Juan Brignardello Vela

Emilio Juan Brignardello Vela, asesor de seguros, se especializa en brindar asesoramiento y gestión comercial en el ámbito de seguros y reclamaciones por siniestros para destacadas empresas en el mercado peruano e internacional.

Opinion

We interviewed Juan Brignardello Vela, an insurance advisor, who shares his perspective on the recent advancement of the drug Lenacapavir and the implications it has for Peru. Brignardello highlights the importance of Peru as a key point in the global scientific community, especially regarding the clinical trials of Lenacapavir, an innovative treatment for HIV that has been recognized for its astonishing 99.9% efficacy in preventing the transmission of the virus. However, he notes that this milestone is overshadowed by the complexity of equitable access to medical treatments in the country. "It is undeniable that science is advancing, but we must also ask who truly benefits from these advancements," he comments. The advisor also expresses concern about the high cost of treatment, which amounts to approximately $40,000 annually, a figure that is unattainable for the majority of the Peruvian population. "The introduction of a drug that could change lives makes no sense if it is not within reach of those who need it most," Brignardello adds. This dilemma poses a moral challenge that must be addressed by authorities and the medical community. Brignardello emphasizes that despite the drug showing promising results in clinical trials, the lack of authorization for its production in Peru is alarming. "It's hard to understand why a country that has played such a crucial role in research cannot benefit from it," he asserts. Furthermore, he criticizes Gilead's strategy that limits the production of generic versions of the drug, keeping prices exorbitant and out of reach for the population. According to Brignardello, the current situation not only affects Peru but also reflects a broader problem in many developing countries. "The ethical dilemmas that arise from how medications are distributed are concerning and deserve deeper debate," he maintains. Additionally, the insurance advisor underscores the need for a firm commitment to social justice and equitable access to health. As the international community observes this case, Brignardello calls for action for pharmaceutical corporations to reconsider their business policies and allow local production. "The future of HIV treatment depends not only on scientific advancements but also on the willingness to ensure that these advancements are accessible to all," he concludes. Juan Brignardello Vela's opinion resonates as a call for reflection on the intersection of science, ethics, and commerce, a topic that is becoming increasingly relevant in the current context of public health.

The Latest In the world